Results 121 to 130 of about 6,675,706 (283)

Secret Distribution of Keys for Public-Key Systems [PDF]

, 1988
This paper proposes new public-key cryptosystems systems the security of which is based on the tamperfreeness of a device and the existence of secret key cryptosystems instead of the computational complexity of a trapdoor one-way function (RSA).
openaire   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

A new quantum-safe multivariate polynomial public key digital signature algorithm. [PDF]

Sci Rep, 2022
Kuang R, Perepechaenko M, Barbeau M.
europepmc   +1 more source

A New Public-Key Cryptosystem [PDF]

, 1997
This paper describes a new public-key cryptosystem where the ciphertext is obtained by multiplying the public-keys indexed by the message bits and the cleartext is recovered by factoring the ciphertext raised to a secret power. Encryption requires four multiplications/byte and decryption is roughly equivalent to the generation of an RSA signature.
David Naccache, Jacques Stern
openaire   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Algorithm for Key Transparency with Transparent Logs [version 2; peer review: 2 approved, 1 approved with reservations, 1 not approved]

Open Research Europe
Background Cryptography plays a crucial role in securing digital communications and data storage. This study evaluates the Transparent Key Management Algorithm utilizing Merkle trees, focusing on its performance and security effectiveness in ...
Shasivar Rexhepi, Ikechukwu John Chukwu, Ridvan Bunjaku, Hasan Dag, Elissa Mollakuqe   +4 more
doaj   +1 more source

An Enhanced Architecture to Resolve Public-Key Cryptographic Issues in the Internet of Things (IoT), Employing Quantum Computing Supremacy. [PDF]

Sensors (Basel), 2022
Shamshad S, Riaz F, Riaz R, Rizvi SS, Abdulla S.   +4 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

How to Construct Polar Codes for Ring-LWE-Based Public Key Encryption. [PDF]

Entropy (Basel), 2021
Wang J, Ling C.
europepmc   +1 more source